The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1528-3658
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells ; volume:27 ; number:1 ; day:7 ; month:5 ; year:2021 ; pages:1-13 ; date:12.2021
Molecular medicine ; 27, Heft 1 (7.5.2021), 1-13, 12.2021
- Urheber
-
Poźniak, Marta
Porębska, Natalia
Krzyścik, Mateusz Adam
Sokołowska-Wędzina, Aleksandra
Jastrzębski, Kamil
Sochacka, Martyna
Szymczyk, Jakub
Zakrzewska, Małgorzata
Otlewski, Jacek
Opaliński, Łukasz
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s10020-021-00306-2
- URN
-
urn:nbn:de:101:1-2021091020201812096483
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Poźniak, Marta
- Porębska, Natalia
- Krzyścik, Mateusz Adam
- Sokołowska-Wędzina, Aleksandra
- Jastrzębski, Kamil
- Sochacka, Martyna
- Szymczyk, Jakub
- Zakrzewska, Małgorzata
- Otlewski, Jacek
- Opaliński, Łukasz
- SpringerLink (Online service)
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
Antibody–nucleotide conjugate as a substrate for DNA polymerases
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Tailored Mobility in a Zeolite Imidazolate Framework (ZIF) Antibody Conjugate **
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Tailored mobility in a zeolite imidazolate framework (ZIF) antibody conjugate
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
Generation of binder-format-payload conjugate-matrices by antibody chain-exchange
Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression
The First FDA-Approved Antibody-Drug Conjugate
Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
Antibody–nucleotide conjugate as a substrate for DNA polymerases
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Tailored Mobility in a Zeolite Imidazolate Framework (ZIF) Antibody Conjugate **
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Tailored mobility in a zeolite imidazolate framework (ZIF) antibody conjugate
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
Generation of binder-format-payload conjugate-matrices by antibody chain-exchange
Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression
The First FDA-Approved Antibody-Drug Conjugate
Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
Antibody–nucleotide conjugate as a substrate for DNA polymerases
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Tailored Mobility in a Zeolite Imidazolate Framework (ZIF) Antibody Conjugate **
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Tailored mobility in a zeolite imidazolate framework (ZIF) antibody conjugate
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
Generation of binder-format-payload conjugate-matrices by antibody chain-exchange